Connect with us
BETA

Beta Drugs Limited (BETA) Stock Analysis

Beta Drugs Limited is an Indian pharmaceutical company focused on formulations and healthcare products. It develops and markets medicines for therapeutic segments served through distributors and chemists. The company competes in the domestic generic and specialty pharma market. It is listed on Indian stock exchanges and operates from India.

Healthcare › Drug Manufacturers - Specialty & Generic
₹1,802.30
-3.67% 1W  |  +9.90% 52W
Market Cap
1.8k CR
P/E Ratio
36.5
52W High
₹2807.9
52W Low
₹990.1
Div. Yield
0%
Beta
-0.3
50 DMA
₹1939.3
200 DMA
₹1735.5
Profit Margin
11.1%
Inst. Own.
0%
Trendline Analysis
📉 CONSOLIDATING DOWN₹2.7k₹2.4k₹2.0k₹1.7k₹1.3k22 May01 Jul06 Aug22 Sep18 Nov5.2L
Fundamentals
Profit & Loss
MetricDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales88941001038794126137
YoY Sales growth-1%+0%+25%+33%
Expenses70768182707698107
Operating Profit1817202117182730
OPM %21%18%20%21%19%19%22%22%
Other Income-12332322
Interest23344432
Depreciation34444545
Profit before tax1212161610122226
Tax %25%26%25%26%19%24%25%25%
Net Profit991212991619
EPS in Rs8.868.9511.5912.118.408.9314.2516.68
Growth — CAGR
Metric3Y5Y10Y
Revenue CAGR19.0%27.0%–
Profit CAGR11.0%29.0%–
Shareholding Pattern
Promoters58.91%
FIIs1.37%
DIIs6.45%
Public33.27%
BETA
Holdings Analysis
Key strengths & risk signals
63
Overall
61
Fundamental
66
Technical
Risks (4)
OVERVALUED! PEG of 3.48 means expensive relative to growth rate.
RECOVERY MODE! Current price (1802.3) above 200-day but below 50-day.
POSITIVE YEAR! Stock gained 9.9% in the last year.
WEAK MOMENTUM! Limited price growth - -3.7% (1 week), 4.8% (1 month), -25.9% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (1939.3) is above 200-day average (1735.5) - positive signal.
LOW VOLATILITY! Beta of -0.30 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 40,216 vs down days: 27,631. Ratio: 1.46x
Fundamental & Technical Analysis
63Overall
61Fundamental
66Technical
Fundamental Breakdown
Growth Quality
24/30
Revenue CAGR: 19.2% (VERY GOOD, 13/15). Profit CAGR: 10.5% (GOOD, 11/15).
Profit Margin
5/10
DECENT EFFICIENCY! 11.1% profit margin - acceptable profitability.
PEG Valuation
3/10
OVERVALUED! PEG of 3.48 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
6/10
MODERATE DEBT! D/E of 0.66 - acceptable leverage.
Public Holding
10/20
SIGNIFICANT PUBLIC HOLDING! 32.93% public ownership - moderate retail influence.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1939.3) is above 200-day average (1735.5) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (1802.3) above 200-day but below 50-day.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
4/10
POSITIVE YEAR! Stock gained 9.9% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 40,216 vs down days: 27,631. Ratio: 1.46x
RSI
3/5
NEUTRAL! RSI at 41.2 - balanced momentum.
52W Range
3/5
MID RANGE! Trading at 44.7% of 52W range - neutral zone.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -3.7% (1 week), 4.8% (1 month), -25.9% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of -0.30 - stable stock, less market risk.
BETA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
QuarterConcallSummary
Q4FY262026-05-22Concall PDF
Q2FY262025-11-13Concall PDF

Peer Comparison

Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
Industry peers
StockPriceP/EProfit MarginRevenue CAGR 5YProfit CAGR 5Y52W ChangeStock StrengthTrendlineYoY ProfitQoQ ProfitYoY RevenueQoQ Revenue
BETA₹1,802.3036.511.1%19.2%10.5%+9.9%63 CONSOLIDATING DOWN+58.2%+22.2%+33.0%+9.6%
VENUSREM₹1,719.5022.413.4%11.6%57.0%+264.9%74 BREAKDOWN+126.2%+85.5%+31.2%+43.9%
HESTERBIO₹2,348.0014.140.1%7.7%27.8%+36.7%73 HIT RESISTANCE+41.7%-79.0%+37.9%+26.8%
WINDLAS₹988.6031.56.8%20.7%16.0%+21.0%76 APPROACHING SUPPORT+1.7%+2.3%+18.7%+6.4%
SYNCOMF₹22.1023.517.2%29.4%56.2%+29.5%78 BREAKDOWN+62.7%+8.9%+16.7%+13.1%
AMRUTANJAN₹516.4026.110.8%9.9%13.3%-27.9%58 APPROACHING RESISTANCE+23.6%+293.2%+14.9%+31.3%
SAKAR₹1,009.7052.514.2%23.6%33.7%+155.1%74 BREAKDOWN+151.1%+9.7%+51.7%+19.7%
JAGSNPHARM₹208.3031.214.3%6.7%17.3%+1.5%69 CONSOLIDATING DOWN-2.4%-6.8%+29.4%+17.3%
Data from TradeAlone · Updated daily